

METABOLIC HEALTH

Retatrutide vs Mounjaro vs Wegovy

A new triple-action medicine just posted the strongest obesity-trial numbers reported so far, though the full peer-reviewed data are still pending.

Swipe

THE CONFUSION

Three names, not one drug

Wegovy, Mounjaro and retatrutide get lumped together as interchangeable. They are not, and only two of the three can actually be started today.

HOW THEY DIFFER

One, two, three pathways

Wegovy works on one hormone pathway (GLP-1). Mounjaro works on two (GIP and GLP-1). Retatrutide works on three (GIP, GLP-1 and glucagon), the first of its kind.

THE REAL-WORLD DATA

Mounjaro tends to deliver more

In a real-world comparison of about 18,400 matched adults, tirzepatide (Mounjaro) users were roughly 1.8x as likely to lose 5%+ of body weight, 2.5x for 10%+, and 3.2x for 15%+, than semaglutide (Wegovy) users, about 7 percentage points more weight loss at one year.

THE NEWCOMER

28% body weight, still investigational

In topline TRIUMPH-1 Phase 3 results, adults on the highest retatrutide dose lost about 28% of their body weight, over 70 lbs, at 80 weeks. It is not yet approved for prescription.

THE REAL DANGER

The risk isn't the drug, it's the vial

A gray market sells these as unregulated research chemicals, self-injected with no medical oversight. No guarantee of purity, dose accuracy or sterility.

THE BOTTOM LINE

Two are ready now, one is worth watching

Both approved options work, and Mounjaro tends to deliver more. Retatrutide has the strongest reported results but is not yet approved.

OUR APPROACH



Prescribed, monitored, never gray-market

Pharmacy-grade medicine means verified purity, exact dosing and sterility, prescribed for your situation and monitored over time. We adopt newer options only once they are approved.